CD19⁺ B cell depletion: a novel strategy to alleviate ischemic stroke damage.

ABSTRACT:

Background

Ischemic stroke, accounting for approximately 80% of all stroke cases, is a major public health challenge and a leading cause of death and disability worldwide. Current treatments primarily involve thrombolytic therapy, limited to a 4.5-hour window due to the risk of complications, underscoring the need for new therapeutic targets. Systemic inflammation plays a critical role in stroke progression, with immune cells infiltrating the brain and exacerbating damage. B cells, in particular, have been implicated in stroke pathogenesis, although their exact role remains contentious. This study examines anti-CD19 antibody (aCD19 Ab) treatment in a stroke model to determine if CD19⁺ B cell depletion can reduce infarct size and alleviate inflammation.

Results

Thi

SUBMITTER: Xu Y 

PROVIDER: S-EPMC12043492 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature